Carvedilol for Portal Hypertension Treatment
Author Information
Author(s): Hamdan Al-Ghamdi
Primary Institution: King Abdulaziz Medical City, Riyadh, Saudi Arabia
Hypothesis
Can carvedilol effectively lower portal pressure and prevent variceal bleeding in cirrhotic patients?
Conclusion
Carvedilol is a promising alternative to traditional treatments for preventing variceal bleeding in patients with portal hypertension.
Supporting Evidence
- Carvedilol showed a lower rate of first variceal bleeding compared to band ligation.
- Patients tolerated carvedilol well, with a discontinuation rate of 15% due to intolerance.
- Chronic administration of carvedilol resulted in a significant reduction in hepatic venous pressure gradient.
Takeaway
Carvedilol is a medicine that helps lower blood pressure in the liver, which can stop dangerous bleeding in people with liver problems.
Methodology
The study compared carvedilol with variceal band ligation in cirrhotic patients to assess the effectiveness in preventing variceal bleeding.
Potential Biases
Potential bias due to the study's design and patient selection criteria.
Limitations
The study primarily involved patients with Child-Pugh class A liver dysfunction, which may limit the generalizability of the results.
Participant Demographics
Cirrhotic patients with grade II or larger esophageal varices.
Statistical Information
P-Value
0.01
Confidence Interval
Not provided
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website